GB201114923D0 - Immunogenic proteins and compositions - Google Patents

Immunogenic proteins and compositions

Info

Publication number
GB201114923D0
GB201114923D0 GB201114923A GB201114923A GB201114923D0 GB 201114923 D0 GB201114923 D0 GB 201114923D0 GB 201114923 A GB201114923 A GB 201114923A GB 201114923 A GB201114923 A GB 201114923A GB 201114923 D0 GB201114923 D0 GB 201114923D0
Authority
GB
United Kingdom
Prior art keywords
compositions
immunogenic proteins
streptococcus
proteins
immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201114923A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GB201114923A priority Critical patent/GB201114923D0/en
Publication of GB201114923D0 publication Critical patent/GB201114923D0/en
Priority to PCT/IB2012/054464 priority patent/WO2013030783A1/en
Ceased legal-status Critical Current

Links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

The invention provides proteins and compositions for the treatment and prevention of Streptococcus agalactiae (Group B streptococcus; GBS).
GB201114923A 2011-08-30 2011-08-30 Immunogenic proteins and compositions Ceased GB201114923D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB201114923A GB201114923D0 (en) 2011-08-30 2011-08-30 Immunogenic proteins and compositions
PCT/IB2012/054464 WO2013030783A1 (en) 2011-08-30 2012-08-30 Immunogenic proteins and compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201114923A GB201114923D0 (en) 2011-08-30 2011-08-30 Immunogenic proteins and compositions

Publications (1)

Publication Number Publication Date
GB201114923D0 true GB201114923D0 (en) 2011-10-12

Family

ID=44838893

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201114923A Ceased GB201114923D0 (en) 2011-08-30 2011-08-30 Immunogenic proteins and compositions

Country Status (2)

Country Link
GB (1) GB201114923D0 (en)
WO (1) WO2013030783A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017523985A (en) * 2014-08-05 2017-08-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Carrier molecule for antigen

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (en) 1985-07-05 1987-12-23 Sclavo Spa GLYCOPROTEIC CONJUGATES WITH TRIVALENT IMMUNOGENIC ACTIVITY
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NL8802046A (en) 1988-08-18 1990-03-16 Gen Electric POLYMER MIXTURE WITH POLYESTER AND ALKANE SULFONATE, OBJECTS THEREFORE.
AU627226B2 (en) 1988-08-25 1992-08-20 Liposome Company, Inc., The Influenza vaccine and novel adjuvants
DE3841091A1 (en) 1988-12-07 1990-06-13 Behringwerke Ag SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
JPH0832638B2 (en) 1989-05-25 1996-03-29 カイロン コーポレイション Adjuvant formulation comprising submicron oil droplet emulsion
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (en) 1989-11-10 1993-06-17 Eniricerche Spa SYNTHETIC PEPTIDES USEFUL AS UNIVERSAL CARRIERS FOR THE PREPARATION OF IMMUNOGENIC CONJUGATES AND THEIR USE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES.
SE466259B (en) 1990-05-31 1992-01-20 Arne Forsgren PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE
GB2276169A (en) 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
IL98715A0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
IT1262896B (en) 1992-03-06 1996-07-22 CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES.
PL170980B1 (en) 1992-06-25 1997-02-28 Smithkline Beecham Biolog Vaccine
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
ES2162139T5 (en) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. VACCINE COMPOSITIONS CONTAINING MONOFOSFORIL-LIPIDO TO 3-O-DISABLED.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
DK1005368T3 (en) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Use of nucleic acids containing non-methylated CpG dinucleotide in combination with alum as adjuvants
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
ES2298316T3 (en) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. WATER OIL EMULSIONS CONTAINING SAPONINS.
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
AU759391B2 (en) 1998-02-12 2003-04-10 Wyeth Holdings Corporation Pneumococcal and meningococcal vaccines formulated with interleukin-12
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
NZ509986A (en) 1998-08-19 2003-10-31 Baxter Healthcare S Immunogenic beta-propionamido-linked polysaccharide and oligosaccharide protein conjugates as vaccines
AU1626199A (en) 1998-12-04 2000-06-26 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A vi-repa conjugate vaccine for immunization against salmonella typhi
MY125202A (en) 1999-03-19 2006-07-31 Smithkline Beecham Biologicals S A Vaccine
JP2002541808A (en) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド Recombinant toxin A protein carrier for polysaccharide conjugate vaccine
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
AU2002347404A1 (en) 2001-09-14 2003-04-01 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
JP4764820B2 (en) 2003-06-23 2011-09-07 バクスター・インターナショナル・インコーポレイテッド Vaccine carrier protein
WO2005028618A2 (en) * 2003-09-15 2005-03-31 Chiron Corporation Immunogenic compositions for streptococcus agalactiae
JP2008508320A (en) * 2004-07-29 2008-03-21 カイロン コーポレイション Immunogenic composition against gram positive bacteria such as STREPTOCOCCUSAGALACTIAE
JP2008518953A (en) 2004-11-01 2008-06-05 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド Streptococcus modified polysaccharides and their use
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
JP5219803B2 (en) 2005-05-13 2013-06-26 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Serum resistance factor of Gram-positive bacteria
US8329184B2 (en) 2005-06-27 2012-12-11 Glaxosmithkline Biologicals S.A. Process for manufacturing vaccines
EP2063911A2 (en) * 2006-07-26 2009-06-03 Novartis Ag Immunogenic compositions for gram positive bacteria
GB0802503D0 (en) 2008-02-11 2008-03-19 Novartis Ag Hybrid polypeptide
CN102481349B (en) * 2009-01-12 2014-10-15 诺华股份有限公司 Cna_b domain antigens in vaccines against gram positive bacteria
GB201003333D0 (en) * 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions

Also Published As

Publication number Publication date
WO2013030783A1 (en) 2013-03-07

Similar Documents

Publication Publication Date Title
MX349948B (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae.
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
IN2015DN01156A (en)
PH12014501991B1 (en) Phenicol antibacterials
NZ730763A (en) Methods of treating a tauopathy
MY172292A (en) Vectors and sequences for the treatment of diseases
NZ707086A (en) Anti-cd40 antibodies and methods of use
SG10201903119QA (en) Polypeptide vaccine
MX2014009289A (en) C10rf32 antibodies, and uses thereof for treatment of cancer.
IN2014DN10386A (en)
GB201118656D0 (en) New compounds
MX366899B (en) New compounds.
IN2014DN10670A (en)
MX354988B (en) Antibody formulations and methods.
MX2013000958A (en) Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma.
IN2014MN02236A (en)
MX357284B (en) Quinone compounds for treating ape1 mediated diseases.
EP4023243A3 (en) Compositions and methods for treating celiac sprue disease
MY165075A (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
MX2014014021A (en) Oligonucleotide chelate complex-polypeptide compositions and methods.
CA2843611C (en) Compositions and methods for reducing the incidence of equine digestive disorders
MX2015008486A (en) Compositions and methods for treating bacterial infections.
IN2015DN02109A (en)
IN2014DN03010A (en)
GB201114923D0 (en) Immunogenic proteins and compositions

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)